$32.36
0.270.84%
At Close: -
$32.36
00.00%
After Hours: Jul 19, 5:07 PM EDT
15 minutes delayed
Comments
Loading...
Collegium Pharmaceutical
COLLNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Collegium Pharmaceutical (NASDAQ:COLL) Stock, Analyst Ratings, Price Targets, Forecasts
Collegium Pharmaceutical Inc has a consensus price target of $36.4 based on the ratings of 7 analysts. The high is $44 issued by Jefferies on June 7, 2024. The low is $22 issued by Cantor Fitzgerald on August 6, 2021. The 3 most-recent analyst ratings were released by Jefferies, Piper Sandler, and Needham on June 7, 2024, May 10, 2024, and April 11, 2024, respectively. With an average price target of $41 between Jefferies, Piper Sandler, and Needham, there's an implied 26.70% upside for Collegium Pharmaceutical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Piper Sandler
Truist Securities
Truist Securities
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Collegium Pharmaceutical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/07/2024 | Buy Now | 35.97% | Jefferies | Glen Santangelo | $41 → $44 | Upgrade | Hold → Buy | Get Alert |
| 05/10/2024 | Buy Now | — | Needham | Serge Belanger | — | Downgrade | Buy → Hold | Get Alert |
| 05/10/2024 | Buy Now | 20.52% | Piper Sandler | David Amsellem | $39 → $39 | Downgrade | Overweight → Neutral | Get Alert |
| 04/11/2024 | Buy Now | 23.61% | Needham | Serge Belanger | → $40 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2024 | Buy Now | 23.61% | Truist Securities | Les Sulewski | $37 → $40 | Maintains | Buy | Get Alert |
| 02/23/2024 | Buy Now | 20.52% | Piper Sandler | David Amsellem | $37 → $39 | Reiterates | Overweight → Overweight | Get Alert |
| 02/02/2024 | Buy Now | 23.61% | Needham | Serge Belanger | → $40 | Reiterates | Buy → Buy | Get Alert |
| 01/04/2024 | Buy Now | 23.61% | Needham | Serge Belanger | $36 → $40 | Maintains | Buy | Get Alert |
| 01/04/2024 | Buy Now | 14.34% | Truist Securities | Gregg Gilbert | $31 → $37 | Maintains | Buy | Get Alert |
| 01/04/2024 | Buy Now | 14.34% | Jefferies | Glen Santangelo | $30 → $37 | Downgrade | Buy → Hold | Get Alert |
| 08/25/2023 | Buy Now | 11.25% | Needham | Serge Belanger | $35 → $36 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | — | HC Wainwright & Co. | Oren Livnat | — | Reiterates | → Neutral | Get Alert |
| 08/04/2023 | Buy Now | 8.16% | Needham | Serge Belanger | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 8.16% | Needham | Serge Belanger | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 8.16% | Needham | Serge Belanger | → $35 | Reiterates | → Buy | Get Alert |
| 05/02/2023 | Buy Now | -7.29% | Jefferies | Glen Santangelo | → $30 | Assumes | → Buy | Get Alert |
| 04/19/2023 | Buy Now | 8.16% | Needham | Serge Belanger | → $35 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | 8.16% | Needham | Serge Belanger | → $35 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | 8.16% | Needham | Serge Belanger | → $35 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | Buy Now | 8.16% | Needham | Serge Belanger | $34 → $35 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 5.07% | Needham | Serge Belanger | $36 → $34 | Maintains | Buy | Get Alert |
| 08/08/2022 | Buy Now | — | HC Wainwright & Co. | Oren Livnat | — | Downgrade | Buy → Neutral | Get Alert |
| 04/06/2022 | Buy Now | 11.25% | Needham | Serge Belanger | $34 → $36 | Maintains | Buy | Get Alert |
| 02/22/2022 | Buy Now | 29.79% | Piper Sandler | David Amsellem | $36 → $42 | Maintains | Overweight | Get Alert |
| 02/15/2022 | Buy Now | -10.38% | HC Wainwright & Co. | Oren Livnat | $26 → $29 | Maintains | Buy | Get Alert |
| 02/15/2022 | Buy Now | 5.07% | Needham | Serge Belanger | $28 → $34 | Maintains | Buy | Get Alert |
| 11/15/2021 | Buy Now | -13.47% | Needham | Serge Belanger | — | Maintains | Buy | Get Alert |
| 11/05/2021 | Buy Now | -19.65% | Needham | Serge Belanger | — | Maintains | Buy | Get Alert |
| 08/06/2021 | Buy Now | -32.01% | Cantor Fitzgerald | Brandon Folkes | — | Downgrade | Overweight → Neutral | Get Alert |
| 08/06/2021 | Buy Now | -1.11% | Needham | Serge Belanger | — | Maintains | Buy | Get Alert |
| 08/06/2021 | Buy Now | -13.47% | HC Wainwright & Co. | Oren Livnat | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Collegium Pharmaceutical (COLL) stock?
The latest price target for Collegium Pharmaceutical (NASDAQ:COLL) was reported by Jefferies on June 7, 2024. The analyst firm set a price target for $44.00 expecting COLL to rise to within 12 months (a possible 35.97% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Collegium Pharmaceutical (COLL)?
The latest analyst rating for Collegium Pharmaceutical (NASDAQ:COLL) was provided by Jefferies, and Collegium Pharmaceutical upgraded their buy rating.
When was the last upgrade for Collegium Pharmaceutical (COLL)?
The last upgrade for Collegium Pharmaceutical Inc happened on June 7, 2024 when Jefferies raised their price target to $44. Jefferies previously had a hold for Collegium Pharmaceutical Inc.
When was the last downgrade for Collegium Pharmaceutical (COLL)?
The last downgrade for Collegium Pharmaceutical Inc happened on May 10, 2024 when Needham changed their price target from N/A to N/A for Collegium Pharmaceutical Inc.
When is the next analyst rating going to be posted or updated for Collegium Pharmaceutical (COLL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Collegium Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Collegium Pharmaceutical was filed on June 7, 2024 so you should expect the next rating to be made available sometime around June 7, 2025.
Is the Analyst Rating Collegium Pharmaceutical (COLL) correct?
While ratings are subjective and will change, the latest Collegium Pharmaceutical (COLL) rating was a upgraded with a price target of $41.00 to $44.00. The current price Collegium Pharmaceutical (COLL) is trading at is $32.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.